Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...

Capricor Therapeutics, Inc. (CAPR) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Capricor Therapeutics leads with Deramiocel for DMD and StealthX tech, backed by trials, NS Pharma deal, and cash. See why CAPR stock is a buy.

Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Below is Validea's guru fundamental report for CAPRICOR THERAPEUTICS INC (CAPR). Of the 22 guru strategies we follow, CAPR rates highest using our Small-Cap Growth Investor model based on the ...

A downtrend has been apparent in Capricor Therapeutics (CAPR) lately with too much selling pressure. The stock has declined 19.3% over the past four weeks. However, given the fact that it is now ...

CAPR generated 30 and 41 million shares volume on the days following its Sept. 27, 2024, announcement to file the BLA with the FDA. Shares surged up to $12.87 before forming parallel descending ...

Capricor Therapeutics Inc CAPR shares are trading lower by 6.05% to $19.27 during Thursday’s session. The company earlier commenced its public offering of common stock.. What To Know: The ...